Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Glycyx gets rights to Valeant's methylnaltrexone bromide for oncology indications

Executive Summary

Valeant Pharmaceuticals International Inc. licensed Glycyx PharmaVentures Ltd. exclusive rights to develop and commercialize therapies containing methylnaltrexone bromide for cancer indications in countries outside the US and Canada.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register